Binary bets on drug approvals for publicly traded biotech companies are no different than going long or short the equity of the biotech company.
The incentive to interfere in drug trials has been around as long as biotech companies have been publicly traded, this changes nothing.
Introducing wildfire prediction markets is an example of something that does not exist and would be reckless and stupid. The stock market already bets on drug trial outcomes.
Comments
Binary bets on drug approvals for publicly traded biotech companies are no different than going long or short the equity of the biotech company.
The incentive to interfere in drug trials has been around as long as biotech companies have been publicly traded, this changes nothing.
Introducing wildfire prediction markets is an example of something that does not exist and would be reckless and stupid. The stock market already bets on drug trial outcomes.